NYSE:PFE - Pfizer Stock Price, News, Headlines & Rumors

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, June 28th. Shareholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer declared that its Board of Directors has authorized a stock buyback plan on Tuesday, December 19th 2017, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. The biopharmaceutical company had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm's revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

20 analysts have issued twelve-month target prices for Pfizer's shares. Their forecasts range from $37.00 to $45.00. On average, they expect Pfizer's share price to reach $41.1176 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for Pfizer.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Pfizer saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 54,661,544 shares, an increase of 5.2% from the July 13th total of 57,638,413 shares. Based on an average daily volume of 20,733,428 shares, the days-to-cover ratio is presently 2.6 days. Currently, 0.9% of the company's stock are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News articles about PFE stock have trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfizer earned a coverage optimism score of 0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.45 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Pfizer.

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.65%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%), Morgan Stanley (0.91%), Dimensional Fund Advisors LP (0.91%) and Fisher Asset Management LLC (0.66%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, Legal & General Group Plc, American Century Companies Inc. and RNC Capital Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Natixis, Fisher Asset Management LLC and Unigestion Holding SA. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $41.08.

Pfizer has a market capitalization of $243.65 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.